Blocked by the sale of Ozmpic Ozmpic, Telesty Startles take less effective medicine

After launching televo I recently lost the ability to sell Accurate copies From patented GLP-1 weight loss medicines, some companies have started to turn to various, less effective medicines that have been on the market in the United States since 2010. Are often considered Online clinics Offering a recipe for weight loss and diabetes medicines – despite its relative old age.

It was initially sold by Novo Nordisk under the names of the Victroza and Saxenda brands, the drug has been accessible in the United States last year. Like ozmpic, liraglutide is an GLP-1 agonist that mimics a naturally occurring hormone and works by suppressing hunger signals and regulating insulin levels. But this does not have the same name or popularity as the newer GLP-1 medicines for a very simple reason: it does not work too, it can cause more severe side effects and patients should inject it daily, not a week.

The FDA has determined earlier this year that patented drugs such as Zepound and Ozmpic are no longer in shortages, terminating regulations that allowed online clinics to sell out of brand, complex versions of medicines. As clinics and manufacturers reduce sales of these compounds, many online clinics and manufacturers cover liraglutide. Leading Telestical Company Hims added Generic Liraglutide to its composition last month, joining a dozen competitors who already offer the product in composite, birth or brand forms.

Large pharmacies, such as Florida -based Olympia, pharmaceutical products, are already being produced by drug production, expecting demand to increase. “We have signed some rather large contracts for Liraglutide,” says Chief Financial Officer Joshua Fritzler. “We can treat it in the same way that we treated semi -giggles and thyrcepatide,” the active ingredients in Ozepik and Zepbound. Fritzler says Olympia plans to start increasing production this summer.

GLP-1 medicines such as Ozepic and Zepbound have been announced because of their unparalleled success in the treatment of obesity and type 2 diabetes. The researchers believe they have and potential To help patients suffering from a wide variety of other conditions, from addiction to Parkinson’s. After the search for GLP-1 has erupted in recent years, the FDA has declared that some of the names of the brand of names are officially in shortages. This meant that doctors could legally prescribe more expensive “complex” versions of semi -glutide and thyrcepatide with the same active ingredients as the originals.

The mixing pharmacies and the startups of the body are thriving by selling these alternative GLP-1 products online, attracting millions of customers who could not afford or do not want to pay higher prices for brand-name drugs that are often not covered by insurance. Now, The shortage of both medicines endedS The FDA Grace period for manufacturers to stop producing and selling sophisticated thyrcepatide is over, and the date of interruption of the half -decay is on May 22. Liraglutide, however were in shortage Since April 2023, so the bands are free to continue to do so.

Some telephone companies continue to offer complex medicines that are said to be not technically direct copies of patented medicines as they are available in personalized doses or with added vitamins. Eli Lily has already judge some of themclaiming that these versions are illegal. Other telephoto companies and connectors play it safely, ending sales completely. (Olympia, for example, stops the production of semaglutide.)